公开(公告)号：US20060222624A1

公开(公告)日：2006-10-05

申请号：US11270276

申请日：2005-11-09

申请人： Tomas Bratt ,  Steen Klysner ,  Finn Nielsen ,  Soren Mouritsen ,  Bjorn Voldborg

发明人： Tomas Bratt ,  Steen Klysner ,  Finn Nielsen ,  Soren Mouritsen ,  Bjorn Voldborg

IPC分类号： A61K38/19 ,  C07K14/525 ,  C07H21/04 ,  C12P21/02 ,  C12N15/74 ,  C12N1/21

CPC分类号： A61K39/0005 ,  A61K38/00 ,  A61K39/001 ,  A61K2039/523 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/525 ,  Y02A50/412

摘要： The present invention provides for an immunogenic analogue of a human TNFα protein, wherein said analogue comprises an immunogenized monomeric TNFα polypeptide or TNFα di- or timer, and wherein the analogue further comprises a toxicity reducing or abolishing mutation selected from the group consisting of Y87S, D143N or A145R, the amino acid numbering setting out from the N-terminal valine in human TNFα. The invention also provides for a nucleic acid fragment encoding the analogue as well as to vectors and transformed cells useful in the preparation of the analogue. Also disclosed are methods of down-regulating TNFα in a subject in need thereof.

摘要翻译： 本发明提供人TNFα蛋白的免疫原性类似物，其中所述类似物包含免疫原化的单体TNFα多肽或TNFα或二价或定时，其中所述类似物还包含毒性降低或消除突变，其选自Y87S， D143N或A145R，人TNFα中N-末端缬氨酸的氨基酸编号。 本发明还提供编码类似物的核酸片段以及用于制备类似物的载体和转化细胞。 还公开了在有需要的受试者中下调TNFα的方法。

公开(公告)号：US20050063952A1

公开(公告)日：2005-03-24

申请号：US10893018

申请日：2004-07-16

申请人： Steen Klysner ,  Bjorn Voldborg

发明人： Steen Klysner ,  Bjorn Voldborg

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  A61K48/00 ,  C12N15/86

CPC分类号： A61K39/0011 ,  A61K2039/523 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/6031 ,  C07K14/70503 ,  Y02A50/412

摘要： The present invention provides for methods for immunizing actively against autologous carcinoembryonic antigen (CEA). The method encompasses that the immune system is engaged with variant CEA which is either administered as a protein vaccine, or is effected expressed by nucleic acid vaccination or live-viral vaccination. Preferred embodiments include immunization with variants that include at least one foreign T-helper epitope introduced in the CEA sequence. Also disclosed is variant proteins, DNA, vectors, and host cells useful for practising the method of the invention.

摘要翻译： 本发明提供了针对自体癌胚抗原（CEA）主动免疫的方法。 该方法包括免疫系统与作为蛋白质疫苗施用的变体CEA接合，或者通过核酸接种或活病毒疫苗接种进行表达。 优选的实施方案包括用包含在CEA序列中引入的至少一种外来T辅助表位的变体免疫。 还公开了可用于实施本发明的方法的变体蛋白质，DNA，载体和宿主细胞。

公开(公告)号：US20070184023A1

公开(公告)日：2007-08-09

申请号：US10577489

申请日：2004-10-28

申请人： Peter Rasmussen ,  Florence Dal Degan ,  Valery Renard ,  Steen Klysner ,  Birgitte Volck

发明人： Peter Rasmussen ,  Florence Dal Degan ,  Valery Renard ,  Steen Klysner ,  Birgitte Volck

IPC分类号： A61K39/385 ,  A61K38/21 ,  C07H21/04 ,  C07K14/475 ,  C12N1/15 ,  C12N1/21 ,  C12N15/63 ,  C12N15/74 ,  C12N15/79 ,  C12N5/04 ,  C12N5/06

CPC分类号： C07K14/52 ,  A61K38/00 ,  A61K39/00 ,  A61K47/61 ,  A61K47/6415 ,  A61K47/642 ,  Y02A50/412

摘要： The present invention provides for novel immunogenic variants of VEGF (vascular endothelial growth factor) which are useful in active specific immunotherapy against diseases that are characterized by overexpression of VEGF. The invention also relates to methods of treating such diseases (for instance cancer) as well as to various tools in molecular biology that assist in the provision of the immunogenic variants.

摘要翻译： 本发明提供VEGF（血管内皮生长因子）的新型免疫原性变体，其可用于针对以VEGF过表达为特征的疾病的活性特异性免疫疗法。 本发明还涉及治疗这些疾病（例如癌症）的方法以及有助于提供免疫原性变体的分子生物学中的各种工具。

公开(公告)号：US07285273B1

公开(公告)日：2007-10-23

申请号：US09980916

申请日：2000-04-19

申请人： Steen Klysner

发明人： Steen Klysner

IPC分类号： A61K39/00 ,  A61K45/00 ,  C12P21/04 ,  C07K1/00

CPC分类号： C07K14/5409 ,  A61K39/00 ,  A61K39/0005 ,  A61K2039/51 ,  A61K2039/53 ,  C07K2319/55

摘要： Improvements in therapy and prevention of conditions characterized by an elevated level of eosinophil leukocytes, i.e. conditions such as asthma and other chronic allergic diseases are disclosed. A method is provided for down-regulating interleukin 5 (IL5) by enabling the production of antibodies against IL5 thereby reducing the level of activity of eosinophils.

摘要翻译： 公开了治疗和预防以嗜酸性粒细胞白细胞水平升高为特征的病症的改善，即哮喘和其它慢性过敏性疾病等疾病。 提供了一种通过使抗IL5抗体产生降低白细胞介素5（IL5）的下调方法，从而降低嗜酸性粒细胞活性的水平。

公开(公告)号：US07056512B1

公开(公告)日：2006-06-06

申请号：US09620586

申请日：2000-07-20

申请人： Steen Klysner ,  Soren Mouritsen ,  Torben Halkier

发明人： Steen Klysner ,  Soren Mouritsen ,  Torben Halkier

IPC分类号： A61K39/00 ,  A61K39/38

CPC分类号： C07K14/475 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K48/00 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55522 ,  C07K2319/00

摘要： Disclosed are novel methods for increasing muscle mass by means of immunization against Growth Differentiation Factor 8 (GDF-8, myostatin). Immunization is preferably effected by administration of analogues of GDF-8 which are capable of inducing antibody production against homologous GDF-8. Especially preferred as an immunogen is homologous GDF-8 which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the tertiary structure of the homologous GDF-8. Also disclosed are nucleic acid vaccination against GDF-8 and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic GDF-8 analogues, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

摘要翻译： 公开了通过免疫接种生长分化因子8（GDF-8，肌生成抑制素）来增加肌肉质量的新方法。 免疫优选通过施用能够诱导针对同源GDF-8的抗体产生的GDF-8的类似物来实现。 特别优选的是作为免疫原的同源GDF-8，其通过引入一个或多个外来的免疫显性和混杂的T细胞表位而被修饰，同时基本上保留了同源的GDF-8的三级结构。 还公开了针对GDF-8的核酸疫苗接种和使用活疫苗的疫苗接种以及用于疫苗接种的方法和装置。 这些方法和手段包括鉴定有用的免疫原性GDF-8类似物的方法，制备类似物和药物制剂的方法，以及核酸片段，载体，转化细胞，多肽和药物制剂。

公开(公告)号：US07070784B1

公开(公告)日：2006-07-04

申请号：US10031342

申请日：2000-07-20

申请人： Torben Halkier ,  Søren Mouritsen ,  Steen Klysner

发明人： Torben Halkier ,  Søren Mouritsen ,  Steen Klysner

IPC分类号： A61K39/00 ,  C07K14/00

CPC分类号： C07K14/475 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K48/00 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55522 ,  C07K2319/00

摘要： Disclosed are novel methods for increasing muscle mass by means of immunization against Growth Differentiation Factor 8 (GDF-8, myostatin). Immunization is preferably effected by administration of analogues of GDF-8 which are capable of inducing antibody production against homologous GDF-8. Especially preferred as an immunogen is homologous GDF-8 which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the tertiary structure of the homologous GDF-8. Also disclosed are nucleic acid vaccination against GDF-8 and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic GDF-8 analogues, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

摘要翻译： 公开了通过免疫接种生长分化因子8（GDF-8，肌生成抑制素）来增加肌肉质量的新方法。 免疫优选通过施用能够诱导针对同源GDF-8的抗体产生的GDF-8的类似物来实现。 特别优选的是作为免疫原的同源GDF-8，其通过引入一个或多个外来的免疫显性和混杂的T细胞表位而被修饰，同时基本上保留了同源的GDF-8的三级结构。 还公开了针对GDF-8的核酸疫苗接种和使用活疫苗的疫苗接种以及用于疫苗接种的方法和装置。 这些方法和手段包括鉴定有用的免疫原性GDF-8类似物的方法，制备类似物和药物制剂的方法，以及核酸片段，载体，转化细胞，多肽和药物制剂。

公开(公告)号：US06746669B1

公开(公告)日：2004-06-08

申请号：US09556818

申请日：2000-04-21

申请人： Steen Klysner

发明人： Steen Klysner

IPC分类号： A61K3820

CPC分类号： C07K14/5409 ,  A61K39/00 ,  A61K39/0005 ,  A61K2039/51 ,  A61K2039/53 ,  C07K2319/55

摘要： The present invention relates to improvements in therapy and prevention of conditions characterized by an elevated level of eosinophil leukocytes, i.e. conditions such as asthma and other chronic allergic diseases. A method is provided for down-regulating interleukin 5 (IL5) by enabling the production of antibodies against IL5 thereby reducing the level of activity of eosinophils. The invention also provides for methods of producing modified IL5 useful in this method as well as for the modified IL5 as such. Also encompassed by the present invention are nucleic acid fragments encoding modified IL5 as well as vectors incorporating these nucleic acid fragments and host cells and cell lines transformed therewith. The invention also provides for a method for the identification of IL5 analogues which are useful in the method of the invention as well as for compositions comprising modified IL5 or comprising nucleic acids encoding the IL5 analogues. The preferred embodiment of the present invention entails the use of variants of IL5, where foreign T helper epitopes are introduced so as to induce production of cross-reactive antibodies capable of binding to autologous IL5.

摘要翻译： 本发明涉及治疗和预防以嗜酸性粒细胞白细胞水平升高为特征的病症，即哮喘和其它慢性过敏性疾病等疾病的改善。 提供了一种通过使抗IL5抗体产生降低白细胞介素5（IL5）的下调方法，从而降低嗜酸性粒细胞活性的水平。 本发明还提供了在该方法中以及对于修饰的IL5本身有用的生产修饰的IL5的方法。 本发明还包括编码修饰的IL5的核酸片段以及掺入这些核酸片段和宿主细胞的载体以及用其转化的细胞系。 本发明还提供了用于鉴定IL5类似物的方法，其可用于本发明的方法以及包含经修饰的IL5或包含编码IL5类似物的核酸的组合物。 本发明的优选实施方案需要使用IL5的变体，其中引入外源T辅助表位，以便诱导能够结合自体IL5的交叉反应性抗体的产生。